Home Tirzepatide Tirzepatide Side Effects
Tirzepatide Side Effects
The gastrointestinal cluster accounts for nearly everything common. The rare things are what the warnings are for.
The most common tirzepatide adverse effects are gastrointestinal: nausea in roughly a quarter to a third of trial participants, diarrhea in roughly a fifth, constipation in roughly one in seven, and vomiting in around one in ten. Most are mild to moderate, cluster around dose increases, and settle with adaptation.
Serious events are uncommon but defined: pancreatitis, gallbladder disease, acute kidney injury usually secondary to dehydration, severe hypersensitivity, hypoglycemia when combined with insulin or a sulfonylurea, and a boxed warning regarding rodent thyroid C-cell tumours.
Frequencies are approximate ranges reported across the SURMOUNT and SURPASS programs. They vary by dose and population and are not a prediction for any individual.
| Effect | Reported frequency | Typical timing |
|---|---|---|
| Nausea | Roughly 25–33% of participants | Typically begins within days of a dose increase, peaks over the following one to two weeks, and fades as the gut adapts. It recurs, usually more mildly, at each escalation. |
| Constipation | Roughly 11–17% of participants | Tends to appear in the first month and, unlike nausea, can persist for months rather than resolving with adaptation. |
| Diarrhea | Roughly 19–23% of participants | Usually appears within the first weeks and after escalations, and typically settles within days. |
| Vomiting | Roughly 8–13% of participants | Clusters in the days after a dose increase. Persistent vomiting at a stable dose is not expected and warrants review. |
| Fatigue | Reported by a minority of patients | Most noticeable in the first two months and after escalations, improving when intake stabilises. |
| Hair loss | Reported in a small percentage, higher at top doses | Typically begins two to four months after rapid weight loss starts and resolves over subsequent months as weight stabilises. |
| Injection site reactions | Reported in a small minority | Appears within hours to a day of injection and usually settles within a few days. |
| Gallbladder problems | Uncommon but recognized | Risk accumulates during the phase of most rapid loss, typically months two through nine. |
| Pancreatitis | Rare | Can occur at any point in treatment. |
| Muscle and lean mass loss | Expected on any substantial weight loss | Occurs throughout active weight loss, with the greatest risk during the steepest phase. |
| Sulfur burps | Commonly reported anecdotally | Usually follows a large or high-fat meal by hours, and is worse in the days after a dose increase. |
| Heartburn and reflux | Reported by a minority | Tends to track meal size and timing more than dose. |
| Headache | Reported by a minority | Most common in the first weeks and after escalations. |
| Dizziness and lightheadedness | Reported by a minority | Most common during rapid loss and after gastrointestinal upset. |
| Low blood sugar | Uncommon with tirzepatide alone | Most likely early in treatment and after dose increases in patients on concomitant glucose-lowering therapy. |
| Kidney effects | Uncommon, usually secondary to dehydration | Risk concentrates during periods of significant vomiting or diarrhea. |
| Thyroid C-cell tumour warning | Boxed warning based on rodent data | The warning applies for the duration of treatment. |
| Eye and vision changes | Uncommon | Most relevant in the first months of treatment in patients with established diabetic eye disease. |
The pattern that explains most symptoms
Almost every common effect traces to one mechanism: the stomach empties more slowly and you eat less. Nausea, reflux, sulfur burps, constipation, fatigue, headache and dizziness are downstream of that single change, which is why the management advice overlaps so heavily.
Discontinuation rates
Adverse-event discontinuation in the pivotal trials ran in the single digits, which is lower than the anecdotal noise suggests. The far larger source of real-world discontinuation is cost.
What to report immediately
Severe abdominal pain radiating to the back, inability to keep fluids down, signs of a systemic allergic reaction, a new neck lump or hoarseness, sudden vision change, or fainting.
Every reported effect, in detail
Nausea
Roughly 25–33% of participants
Constipation
Roughly 11–17% of participants
Diarrhea
Roughly 19–23% of participants
Vomiting
Roughly 8–13% of participants
Fatigue
Reported by a minority of patients
Hair loss
Reported in a small percentage, higher at top doses
Injection site reactions
Reported in a small minority
Gallbladder problems
Uncommon but recognized
Pancreatitis
Rare
Muscle and lean mass loss
Expected on any substantial weight loss
Sulfur burps
Commonly reported anecdotally
Heartburn and reflux
Reported by a minority
Headache
Reported by a minority
Dizziness and lightheadedness
Reported by a minority
Low blood sugar
Uncommon with tirzepatide alone
Kidney effects
Uncommon, usually secondary to dehydration
Thyroid C-cell tumour warning
Boxed warning based on rodent data
Eye and vision changes
Uncommon
Frequently asked questions
Do side effects mean it is working?
No. Response and adverse effects are not correlated in a way that makes symptoms a useful gauge.
Are side effects worse than semaglutide?
The profiles are broadly similar in overall gastrointestinal burden, with indirect comparisons suggesting somewhat more constipation on tirzepatide.
Sources
- US prescribing information for tirzepatide (Zepbound and Mounjaro), Eli Lilly and Company — dosing, storage, warnings and contraindications.
- SURMOUNT-1 — tirzepatide once weekly for the treatment of obesity, NCT04184622.
- SURPASS-2 — tirzepatide versus semaglutide 1 mg in type 2 diabetes, NCT03987919.
- Full source ledger — every primary source with a live link, what it supports, the date we read it, and the claims we deliberately do not source.